Home-based vaccination records and hypothetical cost-savings due to avoidance of re-vaccinating children
Journal Title: Journal of Vaccines & Immunization - Year 2014, Vol 2, Issue 1
Abstract
As national immunization programmes, particularly those in low- and middle-income countries where administrative recording of services received is often absent or sub-optimal, enter a period of rapidly paced change with new vaccine introductions, it seems important to identify ways to avoid unnecessary re-vaccination of children and the associated costs. Some re-vaccination may be unavoidable, while other re-vaccination is almost certainly avoidable but nevertheless occurs. Unfortunately, the prevalence and epidemiology of re-vaccination of children are ill-described, and potential risks due to re-vaccination are either nil or also unknown. Nonetheless, it is seemingly important to better understand avoidable re-vaccinations that occur as a result of a breakdown along the service delivery continuum.
Authors and Affiliations
Brown DW
Keywords
Related Articles
- EP ID EP566666
- DOI 10.14312/2053-1273.2014-e1
- Views 52
- Downloads 0
An evaluation of the indirect cohort method to estimate the effectiveness of the pneumococcal polysaccharide vaccine
We examined the validity of the indirect cohort method as a rapid assessment tool to estimate pneumococcal polysaccharide vaccine effectiveness (VE). Using evidence from published clinical trials, we reviewed the primary...
From package to protection: how do we close global coverage gaps to optimize the impact of vaccination?
The success of every vaccination program is dependent upon reaching and sustaining the target coverage rates. Vaccination programs are currently facing coverage gaps where target coverages are never reached and may also...
Developing a vaccine for human rhinoviruses
Rhinoviruses (RV’s) are common human pathogens of the respiratory tract being the most frequent cause of mild diseases of the upper respiratory tract (common cold) but more importantly they are a major initiator of acute...
Immunogenicity of 13-valent pneumococcal conjugate vaccine in immunocompetent older adults with stable underlying medical conditions
The 13-valent pneumococcal conjugate vaccine (PCV13) elicits robust functional antibody responses in immunocompetent adults aged ≥50 years, including healthy adults and those considered at risk (ie, stable, chronic cardi...
Influenza and pneumococcal vaccination in hospitalized adults with pandemic (H1N1) 2009: Immunization practices and impact on clinical presentation and outcomes
The purpose of this study was to determine vaccination rates against influenza and pneumococcus in a large cohort of adults hospitalized with confirmed influenza A(H1N1) pdm09 infection, and to identify differences in cl...